Prevalence of TPMT and ITPA gene polymorphisms and effect on mercaptopurine dosage in Chilean children with acute lymphoblastic leukemia

BMC Cancer

Mauricio J Farfan²  Carolina Salas²  Cristina Canales¹  Felipe Silva²  Milena Villarroel²  Katherine Kopp²  Juan P Torres²  María E Santolaya²  Jorge Morales² 

[1] Departamento de Pediatría, Centro de Estudios Moleculares, Facultad de Medicina, Universidad de Chile, Antonio Varas 360, Santiago, Chile

[2] Hospital Dr. Luis Calvo Mackenna, Santiago, Chile

关键词: TPMT;    6-Mercaptopurine;    Acute lymphoblastic leukemia (ALL);    Genetic polymorphism;   

Others  :  858858
DOI  :  10.1186/1471-2407-14-299

 received in 2013-02-13, accepted in 2014-04-23,  发布年份 2014

【 摘 要 】

Background

Mercaptopurine (6-MP) plays a pivotal role in treatment of childhood acute lymphoblastic leukemia (ALL); however, interindividual variability in toxicity of this drug due to genetic polymorphism in 6-MP metabolizing enzymes has been described. We determined the prevalence of the major genetic polymorphisms in 6-MP metabolizing enzymes in Chilean children with ALL.

Methods

103 Chilean pediatric patients with a confirmed diagnosis of ALL were enrolled. DNA was isolated from whole blood and genetic polymorphism in thiopurine S-methyltransferase (TPMT) and inosine triphosphate pyrophosphatase (ITPA) coding genes were detected by polymorphism chain reaction-restriction fragment length (PCR-RFLP) assay.

Results

The total frequency of variant TPMT alleles was 8%. TPMT*2, TPMT*3A and TPMT*3B alleles were found in 0%, 7%, and 1% of patients, respectively. For ITPA, the frequency of P32T allele was 3%. We did not observe any homozygous variant for TPMT and ITPA alleles. We also analyzed a subgroup of 40 patients who completed the maintenance phase of ALL treatment, and we found that patients carrying a TPMT gene variant allele required a significantly lower median cumulative dosage and median daily dosage of 6-MP than patients carrying wild type alleles.

Conclusion

TMPT genotyping appears an important tool to further optimize 6-MP treatment design in Chilean patients with ALL.

【 授权许可】

   
2014 Farfan et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Cheok MH, Lugthart S, Evans WE: Pharmacogenomics of acute leukemia. Annu Rev Pharmacol Toxicol 2006, 46:317-353.
• [2]Wall AM, Rubnitz JE: Pharmacogenomic effects on therapy for acute lymphoblastic leukemia in children. Pharmacogenomics J 2003, 3(3):128-135.
• [3]Evans WE, Hon YY, Bomgaars L, Coutre S, Holdsworth M, Janco R, Kalwinsky D, Keller F, Khatib Z, Margolin J, Murray J, Quinn J, Ravindranath Y, Ritchey K, Roberts W, Rogers ZR, Schiff D, Steuber C, Tucci F, Kornegay N, Krynetski EY, Relling MV: Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine. J Clin Oncol 2001, 19(8):2293-2301.
• [4]Cheok MH, Evans WE: Acute lymphoblastic leukaemia: a model for the pharmacogenomics of cancer therapy. Nat Rev Cancer 2006, 6(2):117-129.
• [5]Cao H, Hegele RA: DNA polymorphisms in ITPA including basis of inosine triphosphatase deficiency. J Hum Genet 2002, 47(11):620-622.
• [6]Relling MV, Hancock ML, Rivera GK, Sandlund JT, Ribeiro RC, Krynetski EY, Pui CH, Evans WE: Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst 1999, 91(23):2001-2008.
• [7]Lu HF, Shih MC, Hsueh SC, Chen CM, Chang JY, Chang JG: Molecular analysis of the thiopurine S-methyltransferase alleles in Bolivians and Tibetans. J Clin Pharm Ther 2005, 30(5):491-496.
• [8]Sahasranaman S, Howard D, Roy S: Clinical pharmacology and pharmacogenetics of thiopurines. Eur J Clin Pharmacol 2008, 64(8):753-767.
• [9]Stocco G, Cheok MH, Crews KR, Dervieux T, French D, Pei D, Yang W, Cheng C, Pui CH, Relling MV, Evans WE: Genetic polymorphism of inosine triphosphate pyrophosphatase is a determinant of mercaptopurine metabolism and toxicity during treatment for acute lymphoblastic leukemia. Clin Pharmacol Ther 2009, 85(2):164-172.
• [10]Yates CR, Krynetski EY, Loennechen T, Fessing MY, Tai HL, Pui CH, Relling MV, Evans WE: Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med 1997, 126(8):608-614.
• [11]McLeod HL, Lin JS, Scott EP, Pui CH, Evans WE: Thiopurine methyltransferase activity in American white subjects and black subjects. Clin Pharmacol Ther 1994, 55(1):15-20.
• [12]Relling MV, Gardner EE, Sandborn WJ, Schmiegelow K, Pui CH, Yee SW, Stein CM, Carrillo M, Evans WE, Klein TE: Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing. Clin Pharmacol Ther 2011, 89(3):387-391.
• [13]Alvarez L, Venegas M, Larrondo M, Becerra N, Castro A, Quera R: Thiopurine S-methyltransferase gene polymorphism in Chilean blood donors. Rev Med Chile 2009, 137(2):185-192.
• [14]Boson WL, Romano-Silva MA, Correa H, Falcao RP, Teixeira-Vidigal PV, De Marco L: Thiopurine methyltransferase polymorphisms in a Brazilian population. Pharmacogenomics J 2003, 3(3):178-182.
• [15]Silva MR, de Oliveira BM, Viana MB, Murao M, Romanha AJ: Thiopurine S-methyltransferase (TPMT) gene polymorphism in Brazilian children with acute lymphoblastic leukemia: association with clinical and laboratory data. Ther Drug Monit 2008, 30:700-704.
• [16]Peregud-Pogorzelski J, Tetera-Rudnicka E, Kurzawski M, Brodkiewicz A, Adrianowska N, Mlynarski W, Januszkiewicz D, Drozdzik M: Thiopurine S Methyltransferase (TPMT) Polymorphisms in Children With Acute Lymphoblastic Leukemia, and the Need for Reduction or Cessation of 6-Mercaptopurine Doses During Maintenance Therapy: The Polish Multicenter Analysis. Pediatr Blood Cancer 2011, 57:578-582.
• [17]Relling MV, Pui CH, Cheng C, Evans WE: Thiopurine methyltransferase in acute lymphoblastic leukemia. Blood 2006, 107:843-844.
• [18]Kapoor G, Sinha R, Naithani R, Chandgothia M: Thiopurine S-methyltransferase gene polymorphism and 6-mercaptopurine dose intensity in Indian children with acute lymphoblastic leukemia. Leuk Res 2010, 34(8):1023-1026.
• [19]Marsh S, King CR, Ahluwalia R, McLeod HL: Distribution of ITPA P32T alleles in multiple world populations. J Hum Genet 2004, 49(10):579-581.
• [20]Stocco G, Crews KR, Evans WE: Genetic polymorphism of inosine-triphosphate-pyrophosphatase influences mercaptopurine metabolism and toxicity during treatment of acute lymphoblastic leukemia individualized for thiopurine-S-methyl-transferase status. Expert Opin Drug Saf 2010, 9(1):23-37.